Full text

Turn on search term navigation

© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.

Abstract

Background/Objectives: In connection with previous work on V-shaped polycyclic thiazolo[5,4-f]quinazolin-9-one and [5,4-f]quinazoline derivatives that can modulate the activity of various kinases, the synthesis of straight thiazole-fused [4,5-g] or [5,4-g]quinazolin-8-ones and quinazoline derivatives hitherto undescribed was envisioned. Methods: An innovative protocol allowed to obtain the target structures. The synthesis of inverted thiazolo[4,5-h] and [5,4-h]quinazolin-8-one derivatives was also explored with the aim of comparing biological results. The compounds obtained were tested against a representative panel of eight mammalian protein kinases of human origin: CDK9/CyclinT, Haspin, Pim-1, GSK-3β, CK-1ε, JAK3, CLK1 and DYRK1A. Results and Conclusions: The results obtained show that the novel linear thiazoloquinazolines are not kinase inhibitors. The cytotoxicity of these newly synthesized compounds was assessed against seven representative tumor cell lines (human cancers: Huh7-D12, Caco-2, HCT-116, MCF-7, MDA-MB-231, MDA-MB-468 and PC-3). The majority of these novel molecules proved capable of inhibiting the growth of the tested cells. The 7-Benzyl-8-oxo-7,8-dihydrothiazolo[5,4-g]quinazolinones 5b and 6b are the most potent, with IC50 values in the micromolar range. None of these compounds showed toxicity against normal cells. A larger program of investigations will be launched to investigate the real potential interest of such compounds in anticancer applications.

Details

Title
Novel Thiazole-Fused [4,5-g] or [5,4-g]Quinazolin-8-ones and Their Quinazoline Analogues: Synthesis and Biological Evaluation
Author
Broudic, Nathan 1   VIAFID ORCID Logo  ; Pacheco-Benichou, Alexandra 1 ; Corbière, Cécile 2 ; Baratte, Blandine 3   VIAFID ORCID Logo  ; Thomas, Robert 3 ; Bach, Stéphane 3   VIAFID ORCID Logo  ; Solhi, Hélène 4 ; Rémy Le Guével 4 ; Fruit, Corinne 1   VIAFID ORCID Logo  ; Besson, Thierry 1   VIAFID ORCID Logo 

 Univ Rouen Normandie, INSA Rouen Normandie, CNRS, COBRA UMR 6014, F-76000 Rouen, France; [email protected] (N.B.); [email protected] (A.P.-B.); [email protected] (C.F.) 
 Univ Rouen Normandie, ABTE UR4651, F-76000 Rouen, France; [email protected] 
 Sorbonne Université, CNRS, UMR8227, Integrative Biology of Marine Models Laboratory (LBI2M), Station Biologique de Roscoff, F-29680 Roscoff, France; [email protected] (B.B.); [email protected] (T.R.); [email protected] (S.B.); Sorbonne Université, CNRS, FR2424, Plateforme de Criblage KISSf (Kinase Inhibitor Specialized Screening Facility), Station Biologique de Roscoff, F-29680 Roscoff, France 
 Univ Rennes, Plateform ImPACcell, BIOSIT, F-35000 Rennes, France; [email protected] (H.S.); [email protected] (R.L.G.) 
First page
1452
Publication year
2024
Publication date
2024
Publisher
MDPI AG
e-ISSN
14248247
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
3133131815
Copyright
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.